Evidence map›Paper›PMID 35370811›Full record

ArticleFrontiers in psychiatry2022

BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression.

Francina Fonseca, Joan Ignasi Mestre-Pinto, Rocío Rodríguez-Minguela, Esther Papaseit, Clara Pérez-Mañá, Klaus Langohr, Margherita Barbuti, Magí Farré, Marta Torrens, NEURODEP GROUP

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Francina FonsecaAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Joan Ignasi Mestre-PintoAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Rocío Rodríguez-MinguelaAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Esther PapaseitClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain.
Clara Pérez-MañáClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain.
Klaus LangohrDepartment of Statistics and Operations Research, Universitat Politècnica de Catalunya - BarcelonaTech, Barcelona, Spain.
Margherita BarbutiPsychiatry 2 Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Magí FarréClinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol (IGTP), Badalona, Spain.
Marta TorrensAddiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
NEURODEP GROUP
Universitat Autònoma de Barcelona · ESHospital Del Mar · ESAzienda Ospedaliera Universitaria Pisana · ITHospital del Mar Research Institute · ESHospital Universitari Germans Trias i Pujol · ESUniversitat Politècnica de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Major depressive disorder (MDD) and cocaine use disorder (CUD) are related with disability and high mortality rates. The assessment and treatment of psychiatric comorbidity is challenging due to its high prevalence and its clinical severity, mostly due to suicide rates and the presence of medical comorbidities. The aim of this study is to investigate differences in brain derived neurotrophic factor (BDNF) and cortisol plasmatic levels in patients diagnosed with CUD-primary-MDD and CUD-induced-MDD and also to compare them to a sample of MDD patients (without cocaine use), a sample of CUD (without MDD), and a group of healthy controls (HC) after a stress challenge. Methods: A total of 46 subjects were included: MDD ( Results: After the TSST, Cohen's Conclusion: Results suggest a different pathogenesis for CUD-induced-MDD with higher levels of cortisol and BDNF compared with CUD-primary-MDD. Such variations should imply different approaches in treatment.

Indexed as

brain derived neurotrophic factor (BDNF)cocaine use disordercortisoldepressiondual diagnosis

Identifiers

PMID35370811
PMCPMC8964529
OpenAlexW4220962390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.